Chemomab Therapeutics News

Express News | Chemomab Therapeutics Shares Are Trading Lower. The Company Announced That It Presented Two Scientific Posters Supporting the Clinical Rationale for the Company's Primary Sclerosing Cholangitis Program at EASL 2024

BenzingaJun 6 12:39 ET

Express News | Chemomab Says It Presented Two Scientific Posters Supporting The Clinical Rationale For Company's Primary Sclerosing Cholangitis Program At EASL 2024, For The Study Of Liver

BenzingaJun 6 07:22 ET

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

TEL AVIV, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (NASDAQ:CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with

GlobeNewswireMay 17 07:00 ET

Express News | Chemomab Therapeutics Ltd : Maxim Group Initiates Coverage With Buy Rating; Target Price $4

ReutersMay 13 07:42 ET

Chemomab Therapeutics Ltd. Sponsored ADR (CMMB) Now Trades Above Golden Cross: Time to Buy?

Yahoo FinanceMay 10 09:55 ET

Analysts Offer Insights on Healthcare Companies: Chemomab Therapeutics (CMMB), Fate Therapeutics (FATE) and Disc Medicine (IRON)

TipRanksMay 10 08:30 ET

Express News | Chemomab Therapeutics Shares Are Trading Higher After the Company Reported a Year-over-year Increase in Q1 GAAP EPS Results

BenzingaMay 9 12:47 ET

Express News | Chemomab Therapeutics Q1 2024 GAAP EPS $(0.28) Up From $(0.80) YoY

BenzingaMay 9 07:10 ET

Express News | Chemomab Therapeutics Ltd - Existing Liquidity Resources as of March 31, 2024 Will Enable It to Fund Its Operations Through March 31, 2025

ReutersMay 9 07:09 ET

Chemomab Therapeutics 1Q EPS 1.4c >CMMB

Chemomab Therapeutics 1Q EPS 1.4c >CMMB

Dow JonesMay 9 07:07 ET

Chemomab Therapeutics | 6-K: Report of foreign private issuer (related to financial reporting)

SEC announcementMay 9 07:02 ET · Announcements

Express News | Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

ReutersMay 9 07:00 ET

Chemomab Therapeutics Receives Nasdaq Extension

TipRanksMay 8 07:58 ET

Express News | Chemomab Therapeutics Granted 180-Day Extension By Nasdaq To Regain Compliance With Minimum Bid Price Rule

BenzingaMay 8 07:15 ET

Express News | Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule

ReutersMay 8 07:01 ET

12 Health Care Stocks Moving In Monday's Intraday Session

GainersNRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 39.5% to $2.93 during Monday's regular session. The company's market cap stands at $30.9 million. TC BioPharm (Holdings) (NASDAQ:TCBP) stoc

BenzingaMay 6 12:31 ET

Express News | Chemomab Therapeutics Shares Are Trading Higher After Oppenheimer Upgraded the Stock From Perform to Outperform and Announced a $6 Price Target

BenzingaMay 6 10:20 ET

Express News | Chemomab Therapeutics Ltd. : Oppenheimer Raises to Outperform From Perform

ReutersMay 6 08:31 ET

Chemomab Therapeutics Price Target Announced at $6.00/Share by Oppenheimer

Chemomab Therapeutics Price Target Announced at $6.00/Share by Oppenheimer

Dow JonesMay 6 08:02 ET

Analysts Offer Insights on Healthcare Companies: Andlauer Healthcare Group (OtherANDHF), ACADIA Pharmaceuticals (ACAD) and Chemomab Therapeutics (CMMB)

TipRanksMay 6 07:50 ET